UK biotechnology company IsomAb Ltd announced on Wednesday the appointment of Dr Philip Brainin as chief executive officer and member of the board of directors.

IsomAb is developing isoform-specific antibody therapeutics for atherosclerotic disease. As CEO, Dr Brainin is tasked with taking lead candidate ISM-001 for chronic stable angina (CSA) into clinical development.

ISM-001's preclinical data showing complete restoration of blood flow in severe ischemic disease models supports the company's goal of delivering a disease-modifying treatment for CSA, a condition affecting 9 million patients in the United States alone.

IsomAb said that Dr Brainin is physician-scientist with extensive training in clinical cardiology, and brings a unique combination of cardiovascular medicine, clinical research, and venture investing experience across EU and US biotechnology companies. He has invested in multiple early-stage therapeutics companies, advised boards of directors including for AnaCardio and NephroDI, and has shaped corporate and business development strategies for portfolio companies to enable financing, partnerships, and exits.